Metabolic & Endocrine Regulation

A synthetic pentapeptide and selective growth hormone secretagogue, designed as a ghrelin receptor (GHSR-1a) agonist. Distinguished from earlier growth hormone releasing peptides by its high selectivity — stimulating GH release without significant concurrent effects on cortisol or prolactin in experimental models. Widely used as a reference compound in GH secretagogue research due to its clean pharmacological profile and well-documented receptor binding characteristics.

A synthetic long-acting analogue of Insulin-like Growth Factor-1, engineered with a 13-amino acid N-terminal extension and an arginine substitution at position 3. One of the most widely referenced growth factor peptides in in-vitro research, with a significantly extended functional half-life compared to native IGF-1 due to markedly reduced binding affinity for IGF binding proteins (IGFBPs).

A synthetic modified fragment (176-191) of the human growth hormone polypeptide, isolated for its lipolytic activity independent of GH receptor-mediated growth effects. Designed for enhanced stability relative to the native hGH sequence, and well-characterised as a reference compound in research examining lipid metabolism pathway interactions and adipose tissue signalling dynamics.

A synthetic small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT). Designed for high target specificity and oral bioavailability in research settings, and well-characterised as a reference compound in research examining cellular NAD+ metabolism and adipocyte energy pathway dynamics.

A synthetic decapeptide fragment of the endogenous kisspeptin family, retaining the C-terminal sequence required for receptor activation. Designed to mirror native KISS1R binding activity, and well-characterised as a reference compound in research examining hypothalamic-pituitary-gonadal axis signalling interactions and reproductive endocrine dynamics.

A synthetic small-molecule agonist of the Estrogen-Related Receptor (ERR) nuclear receptor family. A newer research tool compound generating significant interest in metabolic biology and mitochondrial research for its ability to activate ERR-mediated transcriptional programmes in controlled experimental models.

A stabilised synthetic analog of Growth Hormone-Releasing Factor (GRF), supplied at 5mg as a higher-yield laboratory format. Suited to extended research programmes or multi-arm experimental designs requiring consistent, larger-volume supply of this well-characterised GHRH analog.

A 29-amino acid synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH), engineered without the Drug Affinity Complex modification. Designed for short-duration receptor binding studies, allowing researchers to examine acute somatotropic signalling without extended plasma persistence.